CliffBio
small molecule

TOBRADEX

DEXAMETHASONE; TOBRAMYCIN

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameTOBRADEX
Active ingredientDEXAMETHASONE; TOBRAMYCIN
Strength0.1%;0.3%
Dosage formOINTMENT
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalSeptember 1988
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.